Astal Laboratories Ltd

32(2)&(3): No deviation; full utilisation

• Purpose: No deviation in use of funds; funds utilised fully.
• Mode of fund raising: Preferential issue and related methods.
• Date of raising funds: 14-07-2026.
• Amount raised: 306.00 Lakh.
• Monitoring agency: NA.
• Status: Fully utilised.
• Original object unchanged; funds allocated 306 Lakh.

32(2): No deviation; partial utilisation

• Purpose: Deviation not observed; funds utilised equals original allocation.
• Mode: Public issue, rights issue, or preferential issue.
• Date of raising funds: 12-05-2026.
• Amount raised: 441.00 Lakh.
• Funds utilised: 306.00 Lakh.
• Deviation: Nil.
• Status: Partly utilised; balance remains unutilised.
• Original allocation: 306 Lakh; modified allocation: NIL.
• Monitoring agency: NA.

32(3): No deviation; partial utilisation

• Purpose: Deviation not observed; funds utilised 8.99 Lakh.
• Mode: Public issue or preferential.
• Date of raising funds: 25-05-2026.
• Amount raised: 33.85 Lakh.
• Funds utilised: 8.99 Lakh.
• Deviation: Nil.
• Status: Partly utilised; remaining un utilised.
• Original allocation: 33.99 Lakh; modified allocation: NIL.
• Monitoring agency: NA.

Standalone results

• Quarter ended 30-06-2026: Standalone revenue from operations 3,954.62 Lakhs.
• Standalone PAT after tax: 370.69 Lakhs.
• EPS (Standalone): Basic 0.861, Diluted 0.857.
• Year-to-date Standalone revenue: 15,518.68 Lakhs.
• Year-to-date Standalone PAT: 811.55 Lakhs.

Consolidated results

• Quarter ended 30-06-2026: Consolidated revenue 10,107.39 Lakhs.
• Consolidated PAT after tax: 942.17 Lakhs.
• EPS (Consolidated): Basic 2.188, Diluted 2.174.
• Year-to-date Consolidated revenue: 24,934.88 Lakhs.
• Year-to-date Consolidated PAT: 1,470.94 Lakhs.

Meeting Details

• Date: 14 August 2026.
• Venue: Corporate office, The Platina Kondapur Road, Gachibowli, Telangana 500032.

Key Agenda Items

• Unaudited standalone and consolidated results for quarter ended 30 June 2026, with Limited Review Report.

Other Notes

• Trading window closed from 01 July 2026 until 48 hours after conclusion of the meeting.

Dematerialisation status

• Dematerialisation requests for quarter ended June 2026 were processed and results communicated to depositories.
• Securities dematerialised have been listed on stock exchanges where the earlier securities are listed.
• Physical certificates for dematerialisation were mutilated and cancelled; depository name substituted as registered owner within 15 days.

Key Updates

• Board authorises pursuing acquisition of a USFDA/EU-GMP/WHO-compliant pharma unit in India to expand capacity.
• Authorized to raise up to Rs 300 crore via convertible/non-convertible instruments through private placement, subject to approvals.